Legend Biotech Corp
NASDAQ:LEGN

Watchlist Manager
Legend Biotech Corp Logo
Legend Biotech Corp
NASDAQ:LEGN
Watchlist
Price: 23.39 USD 0.13%
Market Cap: 4.3B USD

Legend Biotech Corp
Cash & Cash Equivalents

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Legend Biotech Corp
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Legend Biotech Corp
NASDAQ:LEGN
Cash & Cash Equivalents
$286.7m
CAGR 3-Years
-25%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash & Cash Equivalents
$5.6B
CAGR 3-Years
-22%
CAGR 5-Years
-7%
CAGR 10-Years
-5%
Gilead Sciences Inc
NASDAQ:GILD
Cash & Cash Equivalents
$9.4B
CAGR 3-Years
26%
CAGR 5-Years
-6%
CAGR 10-Years
-4%
Amgen Inc
NASDAQ:AMGN
Cash & Cash Equivalents
$9.4B
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash & Cash Equivalents
$6.3B
CAGR 3-Years
-12%
CAGR 5-Years
3%
CAGR 10-Years
24%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash & Cash Equivalents
$2.5B
CAGR 3-Years
-10%
CAGR 5-Years
10%
CAGR 10-Years
14%
No Stocks Found

Legend Biotech Corp
Glance View

Legend Biotech Corp., an emerging leader in the biotechnology arena, has carved out a niche at the forefront of cellular therapeutics, focusing on transforming cancer treatment paradigms. Born out of the ambition to explore innovative medical frontiers, Legend Biotech embarked on a mission to develop Car-T cell therapies—a personalized form of immunotherapy that employs genetically altered T-cells to target and eradicate cancer cells. With its signature product, Carvykti (ciltacabtagene autoleucel), Legend Biotech has been making waves in the oncology sector. By redirecting the body's own immune system against multiple myeloma, a rare and challenging form of cancer, the company has demonstrated the potential to achieve deep and lasting remissions, bringing hope where conventional treatments may fall short. The financial model of Legend Biotech is driven by strategic partnerships, extensive research and development initiatives, and successful navigation through complex regulatory landscapes. Partnering with Johnson & Johnson's subsidiary Janssen Biotech, the collaboration capitalizes on their combined expertise to advance Car-T technology. Revenues primarily flow from milestone payments upon achieving specific developmental goals, along with royalties derived from global sales of their breakthrough treatments. By investing heavily in R&D and ensuring a robust pipeline of therapeutic candidates, Legend Biotech positions itself for sustainable growth, striving to extend their innovative treatments to a broader range of cancers and, eventually, achieve profitability through expanded indications and market reach.

LEGN Intrinsic Value
78.69 USD
Undervaluation 70%
Intrinsic Value
Price

See Also

What is Legend Biotech Corp's Cash & Cash Equivalents?
Cash & Cash Equivalents
286.7m USD

Based on the financial report for Dec 31, 2024, Legend Biotech Corp's Cash & Cash Equivalents amounts to 286.7m USD.

What is Legend Biotech Corp's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
28%

Over the last year, the Cash & Cash Equivalents growth was -78%. The average annual Cash & Cash Equivalents growth rates for Legend Biotech Corp have been -25% over the past three years , 28% over the past five years .

Back to Top